1.33
0.11 (9.02%)
Penutupan Terdahulu | 1.22 |
Buka | 1.24 |
Jumlah Dagangan | 5,437,370 |
Purata Dagangan (3B) | 4,364,395 |
Modal Pasaran | 263,604,688 |
Harga / Pendapatan (P/E Ke hadapan) | 1.34 |
Harga / Jualan (P/S) | 0.990 |
Harga / Buku (P/B) | 98.42 |
Julat 52 Minggu | |
Tarikh Pendapatan | 5 Aug 2025 |
Margin Keuntungan | -59.03% |
Margin Operasi (TTM) | -34.00% |
EPS Cair (TTM) | -0.850 |
Pertumbuhan Hasil Suku Tahunan (YOY) | -52.80% |
Nisbah Semasa (MRQ) | 1.18 |
Aliran Tunai Operasi (OCF TTM) | -100.11 M |
Aliran Tunai Bebas Leveraj (LFCF TTM) | -80.85 M |
Pulangan Atas Aset (ROA TTM) | -7.17% |
Arah Aliran Pasaran
Jangka Pendek | Jangka Sederhana | ||
Industri | Drug Manufacturers - Specialty & Generic (US) | Bercampur | Bercampur |
Drug Manufacturers - Specialty & Generic (Global) | Bercampur | Bercampur | |
Stok | Esperion Therapeutics, Inc. | Bercampur | Menurun |
AISkor Stockmoo
Konsensus Penganalisis | 4.0 |
Aktiviti Orang Dalam | -3.0 |
Volatiliti Harga | -2.0 |
Purata Bergerak Teknikal | 2.5 |
Osilator Teknikal | 2.0 |
Purata | 0.70 |
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C. |
|
Sektor | Healthcare |
Industri | Drug Manufacturers - Specialty & Generic |
Gaya Pelaburan | Small Value |
% Dimiliki oleh Orang Dalam | 0.57% |
% Dimiliki oleh Institusi | 59.40% |
Pemilikan
Nama | Tarikh | Syer Dipegang |
---|---|---|
Meditor Group Ltd | 30 Sep 2024 | 3,791,300 |
Indaba Capital Management, L.P. | 31 Mar 2025 | 3,000,000 |
Julat 52 Minggu | ||
Julat Harga Sasaran | ||
Tinggi | 16.00 (HC Wainwright & Co., 1,103.01%) | Beli |
Median | 10.00 (651.88%) | |
Rendah | 4.00 (Needham, 200.75%) | Beli |
Purata | 10.00 (651.88%) | |
Jumlah | 2 Beli | |
Harga Purata @ Panggilan | 0.980 |
Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
---|---|---|---|---|
HC Wainwright & Co. | 17 Jun 2025 | 16.00 (1,103.01%) | Beli | 1.09 |
Needham | 07 May 2025 | 4.00 (200.75%) | Beli | 0.870 |
Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
---|---|---|---|---|
HALLADAY BENJAMIN | - | 1.24 | -11 | -14 |
LOOKER BENJAMIN | - | 1.24 | -1,304 | -1,617 |
Jumlah Keseluruhan Kuantiti Bersih | -1,315 | |||
Jumlah Keseluruhan Nilai Bersih ($) | -1,631 | |||
Purata Pembelian Keseluruhan ($) | - | |||
Purata Jualan Keseluruhan ($) | 1.24 |
Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
---|---|---|---|---|---|---|
HALLADAY BENJAMIN | Pegawai | 17 Jul 2025 | Jual (-) | 11 | 1.24 | 14 |
LOOKER BENJAMIN | Pegawai | 17 Jul 2025 | Jual (-) | 1,304 | 1.24 | 1,617 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
Keuntungan Nyata | - |
Keuntungan Tidak Nyata | - |
Dividen Diterima 2025 | - |
Jumlah Untung | - |
Pulangan Purata | - |
Kuantiti (Beli) | - |
Purata Harga (Beli) | - |
Kuantiti (Jual) | - |
Purata Harga (Jual) | - |